ATHENS, Greece, Sept. 28, 2018 /PRNewswire/ --
Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of
Growth Capitalist (https://growthcapitalist.com/2018/09/new-phase-2-data-for-somapacitan-demonstrate-its-potential-as-an-efficacious-once-weekly-treatment-for-childhood-growth-hormone-deficiency/)
ATHENS, Greece, Sept. 28, 2018 /PRNewswire/ --
Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of